» Articles » PMID: 9786561

Intraocular Pressure Control After Contact Transscleral Diode Cyclophotocoagulation in Eyes with Intractable Glaucoma

Overview
Journal J Glaucoma
Date 1998 Oct 24
PMID 9786561
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: The effect of contact transscleral diode cyclophotocoagulation (TDC) on intraocular pressure (IOP) and its safety was determined in eyes with intractable glaucoma.

Methods: The charts of 41 consecutive patients (43 eyes) who underwent the laser procedure were reviewed. After surgery, data were collected from chart entries at I hour, 1 day, 4 to 6 weeks, 4 to 6 months, and at the final visit (6-24 months). Mean differences in IOP before and after treatment were compared using the paired Student t test. Associated complications also were assessed.

Results: The mean +/- standard deviation follow-up period was 11.9+/-5.3 months (range, 6-24 months). One patient who died after 1 month of follow-up and another patient with neovascular glaucoma who underwent an anterior chamber washout 1 week after laser to treat an uncontrolled IOP spike were excluded from the study. Repeat treatment was done in 12 (28%) eyes. At each follow-up visit postoperatively, a significant reduction from preoperative IOP was obtained (mean reduction of 50% at the final visit). At the final visit, 64% of patients achieved an IOP of <22 mmHg and a reduction of > or =20%. An IOP spike occurred in three (7%) eyes. Long-term complications included loss of vision (> or =2 lines) in eight (22%) patients, corneal decompensation in one (2%), phthisis bulbi in one (2%), and corneal graft rejection in one (2%).

Conclusion: Although effective IOP reduction was demonstrated in eyes with intractable glaucoma after TDC, a significant proportion (26%) of eyes had severe long-term complications.

Citing Articles

Combined Endoscopic Cyclophotocoagulation and Phacoemulsification Versus Phacoemulsification Alone in the Glaucoma Treatment: A Systematic Review and Meta-Analysis.

Amaral D, Louzada R, Moreira P, de Oliveira L, Yuati T, Guedes J Cureus. 2024; 16(3):e55853.

PMID: 38590498 PMC: 11001325. DOI: 10.7759/cureus.55853.


Visual prognosis and surgical timing of Ahmed glaucoma valve implantation for neovascular glaucoma secondary to diabetic vitrectomy.

Lee J, Lee Y, Kim T, Park K BMC Ophthalmol. 2023; 23(1):107.

PMID: 36932350 PMC: 10022148. DOI: 10.1186/s12886-023-02846-z.


Clinical efficacy analysis of Ahmed glaucoma valve implantation in neovascular glaucoma and influencing factors: A STROBE-compliant article.

He Y, Tian Y, Song W, Su T, Jiang H, Xia X Medicine (Baltimore). 2017; 96(42):e8350.

PMID: 29049253 PMC: 5662419. DOI: 10.1097/MD.0000000000008350.


Trans-scleral diode laser cyclophotocoagulation for refractory glaucoma after high-risk penetrating keratoplasty.

Rodriguez-Garcia A, Gonzalez-Gonzalez L, Alvarez-Guzman J Int Ophthalmol. 2015; 36(3):373-83.

PMID: 26419547 DOI: 10.1007/s10792-015-0130-2.


Cyclophotocoagulation and cyclocryocoagulation as primary surgical procedures for open-angle glaucoma.

Gorsler I, Thieme H, Meltendorf C Graefes Arch Clin Exp Ophthalmol. 2015; 253(12):2273-7.

PMID: 26338822 DOI: 10.1007/s00417-015-3159-z.